drugset / Trial / NCT02587000
Adenomyosis and Ulipristal Acetate
RandomizedParallel-groupTriple-blindTreatment
Summary
Evaluation of efficiency of selective progesterone receptor modulators (SPRM) (Ulipristal acetate) on bleeding control and pain for patients with adenomyosis and wish to keep fertility.
Timeline
- Start
- 2015-06-16
- Primary completion
- 2018-02-02
- Completion
- 2020-03-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ulipristal Acetate | Unknown | 10 mg | Oral |